治疗佩罗尼病转诊患者的治疗方法
Kristin Fosli Spanfelt1,2, Jakob Kristian Jakobsen1,2
1Department of Urology, Aarhus University Hospital.
一般医生实际上是指皮罗尼.
科学领域:
- 泌尿病学和雄性病学 泌尿和雄性病学
- 医疗保健管理的管理
背景情况:
- 皮罗尼氏病 (PD) 是一种阴茎纤维性疾病,导致曲和性功能障碍.
- PD经常与糖尿病,勃起功能障碍和心血管疾病同时发生.
- 丹麦医疗保险保证PD患者通过GP转诊获得30天的专家接入.
研究的目的:
- 分析丹麦佩罗尼病患者的转诊模式和治疗结果.
- 评估全科医生 (GP) 选专业泌尿器科护理的有效性.
- 根据国家医疗保证,评估公共部门与私营部门的治疗分配.
主要方法:
- 对101名佩罗尼氏病患者的回顾性研究,这些患者于2019年被转诊到奥胡斯大学医院.
- 从丹麦中部地区商业情报门户网站收集的数据.
- 使用REDCap和Excel分析患者的人口统计学,斑块特征,治疗策略和手术结果.
主要成果:
- 在124个转诊病例中,101个符合佩罗尼病的纳入标准.
- 44%的患者被转诊进行手术治疗;28.7%在公共部门接受手术.
- 双边板块更常见的是保守地管理;只有14.8%的板块转移到私营部门.
结论:
- 一般医生证明了对皮罗尼氏病专家护理的有效分拣.
- 大多数患者在公共卫生保健系统内接受治疗,尽管存在能力挑战.
- 目前的转诊实践似乎是平衡的,尽管30天治疗保证可能会影响医疗保健的长期可持续性.
更多相关视频
03:55Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis
Published on: October 18, 2024
04:22Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Peripheral Artery Disease III: Interprofessional Care
